Yingrui Shi

机构：Yunnan Maternal and Child Health, Hunan Cancer Hospital

发表论文 11 篇 · 总被引 285 次 · h-index 4

代表论文

• Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma (2023 · JAMA · 被引 254)
• Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors. (2024 · Journal of Clinical Oncology · 被引 10)
• Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (2022 · Cancer Research · 被引 7)
• Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). (2023 · Journal of Clinical Oncology · 被引 5)
• Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC). (2024 · Journal of Clinical Oncology · 被引 4)
• Advantages of a novel 540° C-arm medical linear accelerator for volume intensity-modulated radiotherapy: An analysis (2024 · Journal of Radiation Research and Applied Sciences · 被引 3)